Pdl Biopharma Inc (PDLI) 3.55 $PDLI
PDL BioPharma Completes Second Tranche Payment Under Royalty Transaction with ARIAD Pharmaceuticals
PR Newswire - Mon Aug 01, 3:02PM CDT
PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that it has funded the second tranche of $50 million to ARIAD Pharmaceuticals, Inc. (ARIAD) (NASDAQ: ARIA) which was due on the first anniversary of the closing date under the terms of the ARIAD Royalty Agreement. This agreement was entered into in July 2015, in exchange for royalties on the net revenues of Iclusig® (ponatinib). As a result of the second tranche payment, under the terms of the ARIAD Royalty Agreement, PDL's royalty percentage will increase to 5.0% of the U.S. and European net revenues of Iclusig and 5.0% of the payments ARIAD receives elsewhere in the world until December 31, 2018 (subject to agreed-upon annual maximum payments). Beginning January 1, 2019 and thereafter, the royalty rate will increase to 6.5% in all jurisdictions and continue until December 31, 2033, subject to a put option of PDL upon the occurrence of specified events and a call option of ARIAD.
ARIA: 9.71 (+0.20), PDLI: 3.55 (+0.03)
PDL BioPharma to Announce Second Quarter 2016 Financial Results on August 4, 2016
PR Newswire - Thu Jul 28, 6:00AM CDT
PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will release its second quarter 2016 financial results for the period ended June 30, 2016, on Thursday, August 4, 2016, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the financial results. A slide presentation relating to the call will be available via the webcast link on the PDL website.
PDLI: 3.55 (+0.03)
PDL BioPharma to Present at the Jefferies 2016 Healthcare Conference
PR Newswire - Wed Jun 01, 6:00AM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the Jefferies 2016 Healthcare Conference next week in New York. The presentation will be webcast live and will occur on Tuesday, June 7, 2016 at 3:30 p.m. EDT.
PDLI: 3.55 (+0.03)
PDL BioPharma Agrees to Equity Investment in Noden Pharma
Zacks Equity Research - Zacks Investment Research - Wed May 25, 9:02AM CDT
PDL BioPharma (PDLI) announced that it has committed to an equity investment in Noden Pharma to acquire global rights to Tekturna and Tekturna HCT.
PFE: 37.31 (+0.42), BMY: 76.19 (+1.38), PDLI: 3.55 (+0.03), NVS: 83.07 (-0.19)
PDL BioPharma Commits to Equity Investment in Noden Pharma for the Acquisition of Tekturna® (aliskiren) and Tekturna HCT® (aliskiren and hydrochlorothiazide)
PR Newswire - Tue May 24, 3:02PM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that PDL has committed to an equity investment in Noden Pharma DAC, a new privately held company (Noden) that has executed a purchase agreement with Novartis AG (Novartis) to acquire exclusive worldwide rights to manufacture, market, and sell the branded prescription medicine product sold under the name Tekturna® and Tekturna HCT® in the United States and Rasilez® and Rasilez HCT® in the rest of the world. The product's active ingredient is aliskiren, which is indicated for the treatment of hypertension. The drug was previously marketed by Novartis and had estimated global sales in 2015 of $154 million. The transactions are expected to close upon Hart-Scott-Rodino regulatory approval or expiration of the related waiting period. PDL's equity investment will ultimately result in an 88% equity interest in Noden. Given this anticipated majority ownership by PDL, the financial statements of Noden will be consolidated with PDL, which is expected to be immediately accretive to PDL's cash earnings.
PDLI: 3.55 (+0.03), NVS: 83.07 (-0.19)
PDL BioPharma Announces First Quarter 2016 Financial Results
PR Newswire - Wed May 04, 3:02PM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the first quarter ended March 31, 2016 including:
PDLI: 3.55 (+0.03)
PDL BioPharma Announces 2016 Second Quarter Dividend
PR Newswire - Wed May 04, 3:01PM CDT
PDL BioPharma, Inc. (NASDAQ: PDLI) today announced that its board of directors has declared a $0.05 per share dividend for the second quarter of 2016. The cash dividend will be paid on June 13, 2016 to all stockholders who own shares of PDL on June 6, 2016, the record date for the second quarter dividend payment.
PDLI: 3.55 (+0.03)
PDL BioPharma to Announce First Quarter 2016 Financial Results on May 4, 2016
PR Newswire - Thu Apr 28, 6:00AM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its first quarter 2016 financial results for the period ended March 31, 2016, on Wednesday, May 4, 2016, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the financial results. A slide presentation relating to the call will be available via the webcast link on the PDL website.
PDLI: 3.55 (+0.03)
SmarTrend Watching for Potential Pullback in Shares of PDL BioPharma After 6.96% Gain
Comtex SmarTrend(R) - Mon Mar 21, 4:59PM CDT
PDL BioPharma (NASDAQ
DLI) traded in a range yesterday that spanned from a low of $3.15 to a high of $3.42. Yesterday, the shares gained 7.0%, which took the trading range above the 3-day high of $3.20 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
PDLI: 3.55 (+0.03)
Watch for PDL BioPharma to Potentially Pullback After Gaining 6.96% Yesterday
Comtex SmarTrend(R) - Mon Mar 21, 4:58PM CDT
PDL BioPharma (NASDAQ DLI) traded in a range yesterday that spanned from a low of $3.15 to a high of $3.42. Yesterday, the shares gained 7.0%, which took the trading range above the 3-day high of $3.20 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
PDLI: 3.55 (+0.03)
3 Tempting Stocks to Avoid
Evan Niu, CFA, Dan Caplinger, and Todd Campbell, The Motley Fool - Motley Fool - Sun Mar 20, 12:00PM CDT
Sometimes it's difficult to distinguish between a value trap and a value buy. Some stocks can look awfully tempting depending on market conditions, and the challenge for investors is to figure out if it's worth taking the plunge. Here are three...
AMBA: 58.85 (+0.87), GPRO: 12.94 (+0.30), AXP: 64.13 (-0.33), QCOM: 61.85 (-0.73), PDLI: 3.55 (+0.03)
How Patent Risk Poses a Big Threat to PDL BioPharma
Todd Campbell and Kristine Harjes, The Motley Fool - Motley Fool - Thu Mar 17, 9:44AM CDT
Developing billion-dollar blockbusters is the Holy Grail of all biotech companies, but investors can be left owning a company that's a fraction of its former self when patents on these drugs expire. Investors in PDL BioPharma may be reminded of...
TEVA: 53.61 (+0.11), PDLI: 3.55 (+0.03)
PDL BioPharma Completes Quarterly Dividend Payment
PR Newswire - Mon Mar 14, 5:00AM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the March 11, 2016, quarterly dividend payment of $0.05 per share to all stockholders owning shares of PDL as of March 4, 2016, the record date.
PDLI: 3.55 (+0.03)
3 Big Risks Biotech Stocks Face
Todd Campbell and Kristine Harjes, The Motley Fool - Motley Fool - Sun Mar 13, 6:22AM CDT
Biotech is a notoriously risky sector. What seems like a sure success one day can easily result in debilitating failure, and companies are constantly making headlines for nosediving in price when expectations fall through. But if you're an investor...
CLDX: 4.67 (+0.05), MNKD: 1.02 (+0.03), PDLI: 3.55 (+0.03)
Zika Virus and Potential Effect on Olympics
ACCESSWIRE - Wed Feb 10, 8:01AM CST
BiotechMarketReport.com identifies PositiveID Corporation (PSID) as a Solution
TRVN: 6.39 (+0.12), XNCR: 19.35 (+0.41), PDLI: 3.55 (+0.03)
Biotechnology Equities Technical Commentary -- Relypsa, PDL BioPharma, Pacific Biosciences of California, and Clovis Oncology
ACCESSWIRE - Tue Feb 09, 7:02AM CST
NEW YORK, NY / ACCESSWIRE / February 9, 2016 / Park Lane Advisor has initiated coverage on the following equities: Relypsa Inc. (NASDAQ: RLYP), PDL BioPharma Inc. (NASDAQ: PDLI), Pacific Biosciences of California Inc. (NASDAQ: PACB), and Clovis Oncology Inc. (NASDAQ: CLVS). Free note on Relypsa can be accessed at http://www.parklaneadvisor.com/ On Monday, February 08, 2016, the NASDAQ Composite ended at 4,283.75, down 1.82%, the Dow Jones Industrial Average declined 1.10%, to finish the day at 16,027.05, and the S&P 500 closed at 1,853.44, down 1.42%. Register for your complimentary reports at the links given below.
PACB: 8.62 (+0.07), CLVS: 15.04 (+0.76), RLYP: 31.83 (-0.11), PDLI: 3.55 (+0.03)
PDL BioPharma, Inc. Shares Just Fell Off a Cliff -- Here's Why
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 02, 3:30PM CST
What: Shares of PDL BioPharma , a biotech company that focuses on purchasing and developing royalty-based patented assets, sank as much as 13% after the company outlined its new dividend policy. So what: According to PDL BioPharma's press...
PDLI: 3.55 (+0.03)
PDL BioPharma to Present at the 2016 BIO CEO & Investor Conference
PR Newswire - Tue Feb 02, 6:00AM CST
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the 2016 BIO CEO & Investor Conference next week in New York City. The presentation will be webcast live and will occur on Tuesday, February 9, 2016 at 4:00 p.m. EST.
PDLI: 3.55 (+0.03)
PDL BioPharma Completes Second Tranche Payment Under Royalty Transaction with ARIAD Pharmaceuticals
PR Newswire - Mon Aug 01, 3:02PM CDT
PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that it has funded the second tranche of $50 million to ARIAD Pharmaceuticals, Inc. (ARIAD) (NASDAQ: ARIA) which was due on the first anniversary of the closing date under the terms of the ARIAD Royalty Agreement. This agreement was entered into in July 2015, in exchange for royalties on the net revenues of Iclusig® (ponatinib). As a result of the second tranche payment, under the terms of the ARIAD Royalty Agreement, PDL's royalty percentage will increase to 5.0% of the U.S. and European net revenues of Iclusig and 5.0% of the payments ARIAD receives elsewhere in the world until December 31, 2018 (subject to agreed-upon annual maximum payments). Beginning January 1, 2019 and thereafter, the royalty rate will increase to 6.5% in all jurisdictions and continue until December 31, 2033, subject to a put option of PDL upon the occurrence of specified events and a call option of ARIAD.
ARIA: 9.71 (+0.20), PDLI: 3.55 (+0.03)
PDL BioPharma to Announce Second Quarter 2016 Financial Results on August 4, 2016
PR Newswire - Thu Jul 28, 6:00AM CDT
PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will release its second quarter 2016 financial results for the period ended June 30, 2016, on Thursday, August 4, 2016, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the financial results. A slide presentation relating to the call will be available via the webcast link on the PDL website.
PDLI: 3.55 (+0.03)
PDL BioPharma to Present at the Jefferies 2016 Healthcare Conference
PR Newswire - Wed Jun 01, 6:00AM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the Jefferies 2016 Healthcare Conference next week in New York. The presentation will be webcast live and will occur on Tuesday, June 7, 2016 at 3:30 p.m. EDT.
PDLI: 3.55 (+0.03)
PDL BioPharma Agrees to Equity Investment in Noden Pharma
Zacks Equity Research - Zacks Investment Research - Wed May 25, 9:02AM CDT
PDL BioPharma (PDLI) announced that it has committed to an equity investment in Noden Pharma to acquire global rights to Tekturna and Tekturna HCT.
PFE: 37.31 (+0.42), BMY: 76.19 (+1.38), PDLI: 3.55 (+0.03), NVS: 83.07 (-0.19)
PDL BioPharma Commits to Equity Investment in Noden Pharma for the Acquisition of Tekturna® (aliskiren) and Tekturna HCT® (aliskiren and hydrochlorothiazide)
PR Newswire - Tue May 24, 3:02PM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that PDL has committed to an equity investment in Noden Pharma DAC, a new privately held company (Noden) that has executed a purchase agreement with Novartis AG (Novartis) to acquire exclusive worldwide rights to manufacture, market, and sell the branded prescription medicine product sold under the name Tekturna® and Tekturna HCT® in the United States and Rasilez® and Rasilez HCT® in the rest of the world. The product's active ingredient is aliskiren, which is indicated for the treatment of hypertension. The drug was previously marketed by Novartis and had estimated global sales in 2015 of $154 million. The transactions are expected to close upon Hart-Scott-Rodino regulatory approval or expiration of the related waiting period. PDL's equity investment will ultimately result in an 88% equity interest in Noden. Given this anticipated majority ownership by PDL, the financial statements of Noden will be consolidated with PDL, which is expected to be immediately accretive to PDL's cash earnings.
PDLI: 3.55 (+0.03), NVS: 83.07 (-0.19)
PDL BioPharma Announces First Quarter 2016 Financial Results
PR Newswire - Wed May 04, 3:02PM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the first quarter ended March 31, 2016 including:
PDLI: 3.55 (+0.03)
PDL BioPharma Announces 2016 Second Quarter Dividend
PR Newswire - Wed May 04, 3:01PM CDT
PDL BioPharma, Inc. (NASDAQ: PDLI) today announced that its board of directors has declared a $0.05 per share dividend for the second quarter of 2016. The cash dividend will be paid on June 13, 2016 to all stockholders who own shares of PDL on June 6, 2016, the record date for the second quarter dividend payment.
PDLI: 3.55 (+0.03)
PDL BioPharma to Announce First Quarter 2016 Financial Results on May 4, 2016
PR Newswire - Thu Apr 28, 6:00AM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its first quarter 2016 financial results for the period ended March 31, 2016, on Wednesday, May 4, 2016, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the financial results. A slide presentation relating to the call will be available via the webcast link on the PDL website.
PDLI: 3.55 (+0.03)
SmarTrend Watching for Potential Pullback in Shares of PDL BioPharma After 6.96% Gain
Comtex SmarTrend(R) - Mon Mar 21, 4:59PM CDT
PDL BioPharma (NASDAQ
DLI) traded in a range yesterday that spanned from a low of $3.15 to a high of $3.42. Yesterday, the shares gained 7.0%, which took the trading range above the 3-day high of $3.20 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. PDLI: 3.55 (+0.03)
Watch for PDL BioPharma to Potentially Pullback After Gaining 6.96% Yesterday
Comtex SmarTrend(R) - Mon Mar 21, 4:58PM CDT
PDL BioPharma (NASDAQ
DLI) traded in a range yesterday that spanned from a low of $3.15 to a high of $3.42. Yesterday, the shares gained 7.0%, which took the trading range above the 3-day high of $3.20 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. PDLI: 3.55 (+0.03)
3 Tempting Stocks to Avoid
Evan Niu, CFA, Dan Caplinger, and Todd Campbell, The Motley Fool - Motley Fool - Sun Mar 20, 12:00PM CDT
Sometimes it's difficult to distinguish between a value trap and a value buy. Some stocks can look awfully tempting depending on market conditions, and the challenge for investors is to figure out if it's worth taking the plunge. Here are three...
AMBA: 58.85 (+0.87), GPRO: 12.94 (+0.30), AXP: 64.13 (-0.33), QCOM: 61.85 (-0.73), PDLI: 3.55 (+0.03)
How Patent Risk Poses a Big Threat to PDL BioPharma
Todd Campbell and Kristine Harjes, The Motley Fool - Motley Fool - Thu Mar 17, 9:44AM CDT
Developing billion-dollar blockbusters is the Holy Grail of all biotech companies, but investors can be left owning a company that's a fraction of its former self when patents on these drugs expire. Investors in PDL BioPharma may be reminded of...
TEVA: 53.61 (+0.11), PDLI: 3.55 (+0.03)
PDL BioPharma Completes Quarterly Dividend Payment
PR Newswire - Mon Mar 14, 5:00AM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the March 11, 2016, quarterly dividend payment of $0.05 per share to all stockholders owning shares of PDL as of March 4, 2016, the record date.
PDLI: 3.55 (+0.03)
3 Big Risks Biotech Stocks Face
Todd Campbell and Kristine Harjes, The Motley Fool - Motley Fool - Sun Mar 13, 6:22AM CDT
Biotech is a notoriously risky sector. What seems like a sure success one day can easily result in debilitating failure, and companies are constantly making headlines for nosediving in price when expectations fall through. But if you're an investor...
CLDX: 4.67 (+0.05), MNKD: 1.02 (+0.03), PDLI: 3.55 (+0.03)
Zika Virus and Potential Effect on Olympics
ACCESSWIRE - Wed Feb 10, 8:01AM CST
BiotechMarketReport.com identifies PositiveID Corporation (PSID) as a Solution
TRVN: 6.39 (+0.12), XNCR: 19.35 (+0.41), PDLI: 3.55 (+0.03)
Biotechnology Equities Technical Commentary -- Relypsa, PDL BioPharma, Pacific Biosciences of California, and Clovis Oncology
ACCESSWIRE - Tue Feb 09, 7:02AM CST
NEW YORK, NY / ACCESSWIRE / February 9, 2016 / Park Lane Advisor has initiated coverage on the following equities: Relypsa Inc. (NASDAQ: RLYP), PDL BioPharma Inc. (NASDAQ: PDLI), Pacific Biosciences of California Inc. (NASDAQ: PACB), and Clovis Oncology Inc. (NASDAQ: CLVS). Free note on Relypsa can be accessed at http://www.parklaneadvisor.com/ On Monday, February 08, 2016, the NASDAQ Composite ended at 4,283.75, down 1.82%, the Dow Jones Industrial Average declined 1.10%, to finish the day at 16,027.05, and the S&P 500 closed at 1,853.44, down 1.42%. Register for your complimentary reports at the links given below.
PACB: 8.62 (+0.07), CLVS: 15.04 (+0.76), RLYP: 31.83 (-0.11), PDLI: 3.55 (+0.03)
PDL BioPharma, Inc. Shares Just Fell Off a Cliff -- Here's Why
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 02, 3:30PM CST
What: Shares of PDL BioPharma , a biotech company that focuses on purchasing and developing royalty-based patented assets, sank as much as 13% after the company outlined its new dividend policy. So what: According to PDL BioPharma's press...
PDLI: 3.55 (+0.03)
PDL BioPharma to Present at the 2016 BIO CEO & Investor Conference
PR Newswire - Tue Feb 02, 6:00AM CST
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the 2016 BIO CEO & Investor Conference next week in New York City. The presentation will be webcast live and will occur on Tuesday, February 9, 2016 at 4:00 p.m. EST.
PDLI: 3.55 (+0.03)
